PATENT Docket No. NB 2019.00

CERTIFICATE OF MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date listed below.

Dated: May 19, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

H. Michael SHEPARD

Serial No.: 10/051,320

Filing Date: January 18, 2002

For: METHODS TO TREAT AUTOIMMUNE

AND INFLAMMATORY

CONDITIONS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 MAY 26 2004

TEGH CENTER 1000/2900

Examiner: Holleran, A.

Group Art Unit: 1642

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO-1449b are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

I. Timing of the Information Disclosure Statement:

This Supplemental Information Disclosure Statement is filed:

1.97(a)).
hin three ication as set

05/24/2004 HVUUNG1 00000011 502518 10051320

01 FC:1806

180.00 DA

	however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-2518 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
This Informa	tion Disclosure Statement is filed:
	After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to charge Deposit Account No.50-2518 referencing billing No. 7008412001 for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.
This Informa	tion Disclosure Statement is filed:
	After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.
The undersig	ned certifies that:
	Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
	No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
II. Copies of	f the Cited Items:
enclosed.	Copies of all of the items listed on the attached Form PTO-1449B are
	Copies of only the following items listed on the attached Form PTO-1449 are enclosed:

Serial No.: 10/051,320 Docket No.: NB 2019.00

	. 🗆	Copies of the items listed in the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. 09/922,405 filed August 3, 2001 and relied upon in this application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).			
		Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.			
III. Concise Explanation of Relevance:					
	\boxtimes	A concise explanation of relevance of the items listed on Form PTO-1449 is not given.			
		A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).			
IV.	Related	Applications:			
		Applicants bring to the Office's attention the following related, co-pending application(s):			
V.	Conclus	ion:			

Citation of the above documents shall not be construed as:

- an admission that the documents are necessarily prior art with respect to the 1. instant invention;
- a representation that a search has been made, other than as described above; or 2.
- an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b). 3.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449b with initials or other appropriate marks. The Commissioner is hereby authorized to charge Deposit Account No. 50-2518, billing reference number: 2023896-7008412001 for any additional fees required in connection with the filing of this Supplemental Information Disclosure Statement.

Respectfully submitted,

Dated: 11/ay 19, 2004

Antoinette F. Konski Registration No. 34,202

Bingham McCutchen LLP

Three Embarcadero Center, Suite 1800 San Francisco, California 94111-4067

Telephone: (650) 849-4950 Facsimile: (650) 849-4800

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO MAY 2 1 2004

Examiner's

Signature

INFORMATION DISCEOSURE STATEMENT BY APPLICA

(use as many sheets as necessary)

Sheet 1

Complete if Known			
Application Number	10/051,320		
Filing Date	1/18/02		
First Named Inventor	H. Michael Shepard		
Art Unit	1617		
Examiner Name	Criares, Theodore J.		
Attorney Docket Number	NB 2019.00		

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	T ²
Initials*	No.1	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	
, ,	1	AUPPERLE, K. et al.,"Regulation of Synoviocyte Proliferation, Apoptosis, and Invasion by the p53 Tumor Suppressor Gene, (April ,1998) American Journal of Pathology, Vol 152, No. 4	
	2	ZUONING, H et al., Dominant-Negative p53 Mutations in Rheumatoid Arthritis, (1999) Arthritis & Fheumatism 42: No. 6, June PP 1088-1092	
	3	International Search Report, International application No. PCT/US02/01361, dtd 16 Dec, 2002	
	4		
	5		1
	6		
	7	MY 28 m	
	8		
	9	577	
	10	FITTING CENTER 1630, 1	
	11		
	12		
	13		
	14		
	15		ļ
•	16		
	17		
	18		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant.	

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date

Considered